Navigation Links
UBM Medica's Cancer Management: A Multidisciplinary Approach Now Updated Online
Date:1/11/2012

ning, diagnosing, staging, prognoses, treatments, and outcomes. Written for both the clinician and patient, the 14th edition also fully presents new information on newly approved FDA drugs and clinical trials, and the latest data from the AJCC Staging Manual. More than 3,400 cancer professionals have provided unanimous praise for the usefulness and thoroughness of this noteworthy reference sourcebook.

"Cancer Management: A Multidisciplinary Approach represents the best of medical education for hematologists and oncologists: the best authors, up-to-date, and concise enough to be usable for clinicians. The online version extends this usefulness for anyone and everywhere in the clinic," says Dr. Haller.

About UBM Medica

Addressing today's healthcare information needs, UBM Medica, a division of UBM plc (UBM.L), delivers strategic, integrated communications solutions and comprehensive reach—online, in print, live, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, drug databases, data services, live events, and other valuable resources, UBM Medica also delivers comprehensive communication solutions for the pharmaceutical and related industries. US websites include PsychiatricTimes.com, CancerNetwork.com, DiagnosticImaging.com, ConsultantLive.com, OBGYN.net, PhysiciansPractice.com and SearchMedica.com.  Employing more than 1,400 people with offices in 29 countries, UBM Medica is headquartered in London.  For more information, visit http://www.ubmmedica.com/

Media contact:
Amy Erdman
Marketing Director
203-523-
'/>"/>

SOURCE UBM Medica
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... A report released,today by The Cornucopia Institute ... formula are seriously endangering the health of,some formula-fed ... Human Breast Milk in the,Laboratory, details research questioning ... produced in laboratories and extracted from,algae and fungus, ...
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
Cached Medicine Technology:Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 2Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) ... September, where issues related to claims involving the pain ... Pennsylvania, Bernstein Liebhard LLP reports. , According to ... website, the meeting is scheduled to take place on ... latest of several Tylenol conferences that have taken place ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many ... suppliers carefully, Top10BestSEOHosting.com is here to announce that ... hosting suppliers in 2014. , JustHost ( http://www.justhost.com/track/seohosts ... top-of-the-line shared hosting plan. The company’s approach to ... is affordable, accessible and powerful enough for anyone ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
(Date:9/1/2014)... CA (PRWEB) September 01, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... The US FDA announced on August 28, that specific ... recalled (Class I) as the device may reverse ... DePuy Synthes Craniomaxillofacial (CMF) Distraction System is an implant ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3
... but not frequency, study suggests , , THURSDAY, April ... 2-year-olds relate to each other affects the quality -- ... "terrible twos." And a child,s temperament plays a role ... to a new study. , Interactions between 60 mothers ...
... 3, 2008 With spring here and,summer fast approaching, ... said, attractive feet are a MUST!, YogaToes(R) are ... feel great. YogaToes(R) beautify feet with passive exercise that,helps ... by tight,shoes, high heels and overexertion., "Women aren,t ...
... MedQuist,Inc. (Pink Sheets: MEDQ.PK) announces that ... hospital in Newburyport, Mass., has selected MedQuist,Technology ... solution,including dictation, transcription and speech recognition. Anna ... and is home to a,nationally recognized Wound ...
... Third Bank,today announced a strategic alliance with GHN-Online ... cycle management services to,the healthcare industry, that will ... healthcare providers. The alliance,will enable Fifth Third Bank ... to payments -- and integrate the data into ...
... Expands Global Product Potential, LEXINGTON, Mass., April ... ) today announced the signing of a,License, Supply ... rights to market VANTAS(R) (histrelin acetate subcutaneous,implant) throughout ... is a,12-month implant for the treatment of advanced ...
... a child for a lifetime, researchers say, , , THURSDAY, April ... United States were victims of maltreatment in 2006 during their ... or neglect during their first week of life, federal officials ... examination of the risk for nonfatal maltreatment of children less ...
Cached Medicine News:Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:New Ten-Minute Foot Exercisers Beautify Feet for Spring and Summer Sandal Season 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 3Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 2Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 2Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 4Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3
2.5mm...
... 12 bevel tip; silicone sleeve ... is opposite curve, Designed for ... Sleeve acts as stop & ... chance of trauma to the ...
Stab incision blades color coded for simple and accurate identification...
Formed 12.0mm from bend to tip; radius is 12.5 mm;, Curved sharp cutting edge requires less pressure to cut the capsule, reducing stress to zonules. 1.5mm long x .75 mm wide...
Medicine Products: